Florbetaben for Imaging of Vascular Amyloid
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation
About this trial
The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.
Eligibility criteria
Qualifiers
suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA/stroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;
stable symptoms and hemodynamics;
age >/= 18 years;
given informed consent.
Disqualifiers
a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;
severe LV dysfunction (EF<30%);
severe valve disease requiring intervention;
decompensated heart failure;
Trial design
Treatments tested in this trial
- [18F]-Florbetaben PET and CT imaging
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov